Paper published in a journal (Scientific congresses and symposiums)
Evaluation of Everolimus (EVE) in HER2+ advanced breast cancer (BC) with activated PI3K/mTOR pathway : exploratory biomarker observations from the BOLERO-3 trial
JERUSALEM, Guy; ANDRE, Fabrice; CHEN, Davidet al.
2013 • In European Journal of Cancer, 49 (Supplement 3), p. 8
JERUSALEM, Guy ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale
ANDRE, Fabrice; Institut Gustave Roussy - IGR
CHEN, David; Novartis Pharmaceuticals, East Hanover, New Jersey, USA
ROBINSON, Douglas; Novartis Pharmaceuticals, East Hanover, New Jersey, USA
OZGUROGLU, Mustafa; Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey
LANG, Istvan; Orszagos Onkologiai Intézet, Budapest, Hungary
WHITE, Michelle; Monash Medical Center Moorabbin, Victoria, Australia
TOI, Masakazu; Kyoto University, Kyoto, Japan
TARAN, Tetiana; Novartis Pharmaceuticals, East Hanover, New Jersey, USA
GIANNI, Luca; Ospedale San Raffaele, Milan, Italy
Language :
English
Title :
Evaluation of Everolimus (EVE) in HER2+ advanced breast cancer (BC) with activated PI3K/mTOR pathway : exploratory biomarker observations from the BOLERO-3 trial
Publication date :
September 2013
Event name :
17th ECCO - 38th ESMO - 32nd ESTRO European Cancer Congress
